Streck supply agreements, 9/16
September 2016—Streck and Biodesix, a molecular diagnostics company that develops blood-based tests in oncology, have signed an agreement to make Streck the exclusive supplier of DNA and RNA tubes for Biodesix.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Calibration verification/linearity test kits, 9/16
September 2016—LGC Maine Standards released its Validate Tumor Markers and Validate Whole Blood Glucose calibration verification/linearity test kits.
myChoice HRD increases eligible patients, 8/16
August 2016—Myriad Genetics announced that its myChoice HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib, an investigational oral PARP inhibitor being developed by Tesaro. The announcement follows results of the NOVA study, which evaluated the safety and efficacy of niraparib as a maintenance therapy in more than 500 patients with recurrent ovarian cancer.
Blood collection device, 8/16
August 2016—Streck’s Cell-Free DNA BCT, for the collection and preservation of whole blood samples, is available as a 2.0 mL draw tube. The formaldehyde-free preservative reagent contained in Cell-Free DNA BCT inhibits nuclease-mediated degradation of cf-DNA and stabilizes nucleated blood cells, which prevents the release of cellular genomic DNA. Samples are stable for up to 14 days at temperatures between 6°–37°C, allowing convenient sample collection, transport, and storage.
Liquid biopsy PD-L1 test, 8/16
August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy.
FISH slide hybridizer, 8/16
August 2016—Boekel Scientific introduced its RapidFISH slide hybridizer designed to simplify fluorescence in situ hybridization procedures for formalin-fixed, paraffin-embedded tissue samples, cell suspensions, and other tissue preparation procedures. The RapidFISH has a self-clamping slide tray design that maintains the required humidity and has an easy-to-use control system for temperature, time, and controlled temperature steps.
Ergonomically designed microscope, 8/16
August 2016—The Olympus BX46 microscope’s specially designed ergonomic features aim to provide enhanced operator comfort during long hours of use.
Gross room lab tray, 8/16
August 2016—Safety-Spec, a pathologist-owned company, has announced that the Gross Room Lab Tray is available for order on its website, Safety-Spec.com. Designed by a pathologist and laboratory scientist, the tray provides improved specimen organization in the gross room queue, resulting in increased efficiency and patient safety by reducing the potential for misidentification of specimens from a patient (intra-accession mislabeling) as well as misidentification between patients (inter-accession mislabeling).
Studies cite utility of molecular cancer classification test, 8/16
August 2016—A study published in Oncotarget (Brachtel EF, et al. Epub ahead of print March 28, 2016) demonstrates the high accuracy and success rate of Biotheranostics’ CancerType ID molecular cancer classifier in the diagnosis of cancer for specimens with limited tissue. Results from the study support additional clinical utility for CancerType ID in small biopsy and cytology cases.
D-dimer test kit, 8/16
August 2016—LGC Maine Standards announced its Validate D-Dimer calibration verification/linearity test kit has received 510(k) clearance for use on Instrumentation Laboratory’s ACL TOP hemostasis test systems. The kit evaluates D-dimer in a human-plasma base matrix, is prepared using the CLSI recommended “equal delta” method for linearity testing, and is liquid, ready to use.